Abstract
The weaver mutant mouse has a genetic defect that results in the loss of dopamine neurons in the nigrostriatal pathway. Striatal tyrosine hydroxylase and dopamine content are reduced by 60–70%, and dopamine uptake is reduced by as much as 95%. Deficits in all three of these striatal dopamine markers are seen as early as postnatal d 3. The striatal dopamine systems in the weaver apparently have the ability to compensate for this dopamine deficit. Thus, in the weaver, in vitro resting release, as well as amphetamine-evoked fractional release of endogenous dopamine are increased. An additional change seen in the weaver striatum is an elevated serotonin content. These alterations may play an adaptive role in attempting to compensate for the dopamine loss. In summary, the weaver mutant mouse has dramatic deficits in the nigrostriatal pathway, but also seems to develop certain adaptive mechanisms in dopaminergic and other transmitter systems that may compensate functionally for the dopamine deficit. Thus, the weaver mouse provides a unique animal model for studying naturally induced neuronal degeneration that complements those models using surgical and pharmacological protocols.
Similar content being viewed by others
References
Rakic P. and Sidman R. L. (1973)J. Comp. Neurol. 152, 103–132.
Schmidt M. J., Sawyer B. D., Perry K. W., Fuller R. W., Foreman M. M., and Ghetti B. (1982)J. Neurosci. 2, 376–380.
Gupta M., Felten D. L., and Ghetti B. (1988)Brain Res. 402, 379–382.
Triarhou L. C., Norton J., and Ghetti B. (1988)Exp. Brain Res. 70, 256–265.
Ghetti B. and Triarhou L. C. (1992) inProgress in Parkinson's Disease Research, vol. 2 (Hefti F. and Weiner W. J., ed.), Futura, Kisco, NY, p. 375.
Lane J. D., Nadi N. S., McBride W. J., Aprison M. H., and Kusano K. (1977)J. Neurochem. 29, 349,350.
Roffler-Tarlov S. and Graybiel A. M. (1984)Nature 307, 62–66.
Richter J. A., Stotz E. H., Ghetti B., and Simon J. R. (1992)Neurochem. Res. 17, 437–441.
Doucet G., Brundin P., Seth S., Murata Y., Strecker R. E., Triarhou L. C., Ghetti B., and Björklund A. (1989)Exp. Brain Res. 77, 552–568.
Roffler-Tarlov S., Pugatch D., and Graybiel A. M. (1990)J. Neurosci. 10, 734–740.
Simon J. R. and Ghetti B. (1992)Neurochem. Res. 17, 431–436.
Kaseda Y., Ghetti B., Low W. C., Richter J. A., and Simon J. R. (1987)Brain Res. 422, 178–181.
Pullara J. M. and Marshall J. F. (1989)Brain Res. 480, 225–233.
Kaseda Y., Ghetti B., Low W. C., Norton J., Brittain H., Triarhou L. C., Richter J. A., and Simon J. R. (1990)Exp. Brain Res. 83, 1–8.
Roffler-Tarlov S., Graybiel A. M., Martin B., and Kauer J. (1987)Soc. Neurosci. Abstr. 13, 1599.
Ghetti B. and Triarhou L. C. (1992)Soc. Neurosci. Abstr. 18, 156.
Simon J. R., Yu H., Richter J. A., Vasko M. R., and Ghetti B. (1991)J. Neurochem. 57, 1478–1482.
Bostwick J. R. and Le W.-D. (1991)Anayt. Biochem. 192, 125–130.
Lowly O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951)J. Biol. Chem. 193, 265–275.
Robinson T. E. and Wishaw I. Q. (1988)Brain Res. 450, 209–224.
Castaneda E., Wishaw I. Q., Lermer L., and Robinson T. E. (1990)Brain Res. 508, 30–39.
Starke K., Reimann W., Zumstein A., and Hertting G. (1978)Naunyn Schmiedebergs Arch. Pharmacol. 305, 27–36.
Arbilla S. and Langer S. Z. (1981)Eur. J. Pharmacol. 76, 345–351.
Arbilla S., Langer S. Z., and Lehmann J. (1981)Br. J. Pharmacol. 74, 226P.
Cubeddu L. X. and Hoffmann I. S. (1982)J. Pharmacol. Exp. Ther. 223, 497–501.
Blandina P., Goldfarb J., Craddock-Royal B., and Green J. P. (1989)J. Pharmacol. Exp. Ther. 251, 803–809.
Clow D. W. and Jhamandas K. (1989)J. Pharmacol. Exp. Ther. 248, 722–728.
Stotz E. H., Triarhou L. C., Ghetti B., and Simon J. R. (1993)Brain Res. 606, 267–272.
Stachowiak M. K., Bruno J. P., Snyder A. M., Stricker E. M., and Zigmond M. J. (1984)Brain Res. 291, 164–167.
Berger T. W., Kaul S., Stricker E. M., and Zigmond M. J. (1985)Brain Res. 336, 354–358.
Snyder A. M., Zigmond M. J., and Lund R. D. (1986).J. Comp. Neurol. 245, 274–281.
Bruno J. P., Jackson D., Zigmond M. J., and Stricker E. M. (1987)Behav. Neurosci. 101, 806–811.
Luthman J., Bolioli B., Tsutsumi T., Verhofstad A., and Jonsson G. (1987)Brain Res. Bull. 19, 269–274.
Towle A. C., Criswell H. E., Maynard E. H., Lauder J. M., Joh T. H., Mueller R. A., and Breese G. R. (1989)Pharmacol. Biochem. Behav. 34, 367–374.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simon, J.R., Ghetti, B. The weaver mutant mouse as a model of nigrostriatal dysfunction. Mol Neurobiol 9, 183–189 (1994). https://doi.org/10.1007/BF02816118
Issue Date:
DOI: https://doi.org/10.1007/BF02816118